Related Experiment Video

Updated: Dec 24, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K

Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and

Rasmus Stilling Tougaard1,2, Anders Jorsal1,2, Lise Tarnow3

  • 1Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Scandinavian Cardiovascular Journal : SCJ
|April 16, 2020
PubMed

Insights

Liraglutide significantly increased heart rate (HR) in chronic heart failure (CHF) patients with sinus rhythm over six months. This HR increase was not linked to adverse cardiovascular events, but its long-term implications require further study.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Liraglutide, a GLP-1 agonist, shows cardiovascular benefits but can increase heart rate (HR).
  • Potential HR increase and cardiovascular event risk in chronic heart failure (CHF) patients treated with liraglutide warrant investigation.

Purpose of the Study:

  • To investigate associations between HR changes and clinical parameters, laboratory values, echocardiographic findings, and clinical events in liraglutide-treated CHF patients.
  • To assess the impact of liraglutide on HR in CHF patients with varying heart rhythm statuses.

Main Methods:

  • A sub-study of the LIVE trial involving 241 CHF patients (LVEF ≤45%) randomized to liraglutide (1.8mg/day) or placebo for 24 weeks.
  • HR and arrhythmias analyzed via ECG (N=117) and cardiac implanted electronic device readouts (N=20).

Main Results:

  • Liraglutide increased HR by 8-9 bpm in patients with sinus rhythm (SR) compared to placebo (p<.005).
  • HR increases correlated with liraglutide dosage (p=.01) and were not observed in patients without SR.
  • No serious cardiac adverse events were associated with liraglutide-induced HR changes.

Conclusions:

  • Liraglutide treatment led to a substantial HR increase in CHF patients with SR over 6 months.
  • The observed HR increase was not associated with adverse clinical events during the study period.
  • Long-term clinical significance of liraglutide-associated HR elevation in CHF patients remains to be determined.

Keywords:
Type 2 diabetesarrhythmiascardiovascular eventsheart failureincretin hormones

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
370
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
969
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
205
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
159
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
237